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Abstract
Diagnosis of McArdle disease is frequently delayed by many years following the first presentation of symptoms to a health professional. The
aim of this study was to investigate the importance of misdiagnosis in delaying diagnosis of McArdle disease. The frequency of misdiagnosis,
duration of diagnostic delay, categories of misdiagnoses and inappropriate medical interventions were assessed in 50 genetically confirmed
patients. The results demonstrated a high frequency of misdiagnosis (90%, n = 45/50) most commonly during childhood years (67%; n = 30/45)
compared with teenage years and adulthood (teenage: n = 7/45; adult n = 5/45; not known n = 3/45). The correct diagnosis of McArdle disease was
rarely made before adulthood (median age of diagnosis 33 years). Thirty-one patients (62%) reported having received more than one misdiagnosis;
the most common were “growing pains” (40%, n = 20) and “laziness/being unfit” (46%, n = 23). A psychiatric/psychological misdiagnosis was
significantly more common in females than males (females 6/20; males 1/30; p < 0.01). Of the 45 patients who were misdiagnosed, 21 (47%)
received incorrect management. This study shows that most patients with McArdle disease received an incorrect explanation of their symptoms
providing evidence that misdiagnosis plays an important part in delaying implementation of appropriate medical advice and management to this
group of patients.
© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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1. Introduction
McArdle disease (GSDV) is an autosomal recessive disorder
characterised by the absence of muscle glycogen phosphorylase.
The enzyme deficit results in impaired muscle metabolism
with symptoms such as exercise intolerance and muscle pain
beginning in childhood. Muscle pain occurs within a few minutes
of starting physical activity and can lead to muscle contracture
and rhabdomyolysis (RM) if that activity persists or is more
vigorous. Muscle contracture and RM in McArdle disease do
not just follow exercise and can also be triggered by sustained
isometric muscle contraction in everyday activities or ‘unusual’
circumstances [1,2]. RM may result in potential life-threatening
complications requiring urgent hospital admission such as
compartment syndrome and acute kidney failure (Table 1).
Early diagnosis, ideally when the individual is still a child,
is important to facilitate learning the life skills required to
manage the condition and prevent RM [3]. Timely diagnosis
facilitates appropriate screening, management and prevention
of known comorbidities associated with the condition such
as sedentariness and obesity [4]. Currently, a correct diagnosis
frequently occurs years after first presentation of symptoms
[5–8]. This could, in part, be due to its rarity, as doctors might
not be familiar with the clinical hallmarks of the condition
such as the second wind phenomenon, which occurs after about
8–10 minutes of aerobic activity when the symptoms of exercise
intolerance (tachycardia, myalgia and fatigue) disappear and
the patient can exercise more freely.
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To investigate the consequences of disease misdiagnosis in
McArdle disease patients, a service evaluation was performed
to assess the frequency of misdiagnosis, the duration of diagnostic
delay, the categories of misdiagnoses and inappropriate medical
interventions.
2. Materials and methods
Clinical information from 50 consecutive patients with
genetically confirmed GSDV (median age: 48.14; range: 16–73;
30 male, 20 female) was reviewed as part of service evaluation
of a ‘Nationally Commissioned Highly Specialized McArdle’s
Disease Service’ based in London. The study was registered
and approved by the Hospital’s internal review board/audit
committee. As this was a service evaluation, informed consent
was not required. Detailed data on diagnosis and misdiagnosis
are routinely collected as part of patients’ assessment at the
UK specialised service. Further information is also available
on NHS referral documentation and GP records/referral letter.
Data related to onset of symptoms, year of diagnosis and related
misdiagnoses, self-perception of GSDV symptoms and incorrect
treatment prescription were collected via medical notes review
and patients’ personal experience reports using a standardised
pre-agreed data extraction form. All data were anonymised,
and individual details and precise description of various
misdiagnoses and incorrect treatment that could potentially
identify an individual were omitted. In patients where more
than one misdiagnosis had occurred, we reported data based
on the age at the first misdiagnosis. Non-parametric data are
summarised as median (range). Categorical data are summarised
as percentages. Gender differences were assessed using
Mann–Whitney U tests for continuous variables and chi-squared
tests for proportions.
3. Results
The frequency of misdiagnosis in patients with GSDV was
90% (n = 45/50). First misdiagnosis most frequently occurred
during childhood years (67%; n = 30/45), and less frequently
during teenage years or adulthood (teenage: n = 7/45; adult
n = 5/45; not known n = 3/45). However, ongoing or additional
misdiagnoses were common through adult years with the
median age of correct diagnosis being 33 years (range 6–70).
The median delay in correct diagnosis of GSDV was 29 years
(range 0–68). The median time from symptom onset to
receiving the first misdiagnosis was 3 years (range 0–67). The
median time from the misdiagnosis to correct diagnosis was 23
years (range 1–62). There were no significant gender
differences in any of these parameters. The diagnostic delay
from the first symptoms to the correct diagnosis appeared to
decrease over the decades (Fig. 1A). This decrease was
associated with an increase in GSDV diagnostic rates with time
(Fig. 1B).
Thirty-one patients (62%) reported having received more
than one misdiagnosis, with “growing pains” (40%, n = 20) and
“laziness/being unfit” (46%, n = 23) representing the most
common misdiagnoses (Fig. 2). A psychiatric/psychological
misdiagnosis was significantly more common in females than
Table 1
McArdle disease diagnostic features.
McArdle disease features Medical history/Physical exam
Exertion intolerance Episodes of muscle pain and tachycardia at the beginning of any physical activity and during strenuous activity,
isometric muscle contraction and/or resistance training. All skeletal muscles are involved.
In children symptoms reported by parents include:
• Infancy: difficulty crawling more than a few yards
• Toddlers: wanting to be carried/or put in a push-chair all of the time, complaining of pain when walking
• Children:
○ unable to run (maximum running distance 100 m)
○ unable to keep up with peers
○ collapse/vomiting during sporting activities
Muscle contracture Severe rigidity with associated pain (patients might report it as “muscle seizes up”, “severe cramp”). Muscle
contracture may affect any skeletal muscle, for example the forearm, with activities such as opening cans,
picking up heavy pots, carrying shopping.
Second wind During aerobic activity symptoms improve after 8–10 minutes.
The second wind can be identified with functional exercise testing with cardiac monitoring such as the 12 minute
walk test or cycle ergometry [7,9–11].
Episodes of rhabdomyolysis/myoglobinuria Severe muscle contracture followed by muscle swelling and pain; flu-like symptoms
Discolouration of urine described as: tea, red wine or coca cola
With severe episodes there may be collapse and acute renal failure
CK is markedly raised (40,000–250,000 IU/L)
Additional investigation Baseline serum CK is usually raised (10–15× normal)
Serum urate is frequently raised
Non-ischemic forearm exercise test shows no significant rise in lactate
DNA analysis:
Initial screen for common mutations in Northern Europeans (p.Arg50X and p.Gly205Ser)
Next tier full PYGM sequencing
Muscle biopsy rarely required: vacuolar myopathy, sub-sarcolemmal glycogen deposition and absent muscle
glycogen phosphorylase activity
CK, creatine kinase.
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males (females 6/20; males 1/30; p < 0.01), but there weren’t
significant gender differences in the other categories. Notably
six patients self-diagnosed their GSDV following library or
internet searches. Of the 45 patients who were misdiagnosed, 21
(47%) received incorrect management, with 13 (29%) receiving
inappropriate exercise training advice (e.g. being advised to
ignore symptoms of pain during exercise, or alternatively, being
advised to avoid exercise altogether) and 12 (27%) receiving
another medical intervention including antibiotic prescription,
sternum surgery, tonsillectomy and invasive procedures such
as cystoscopy [2]. Inappropriate exercise prescription that was
too intense following a misdiagnosis of “laziness/being unfit”
resulted in muscle damage and RM in a few patients. A few
patients reported that, prior to diagnosis, bullying at school was
a problem especially during physical education lessons, causing
further emotional stress.
4. Discussion
A correct diagnosis is rarely identified before adulthood in
people with GSDV with a median age of diagnosis of 33 years,
despite symptoms starting at a median of 3 years of age. This
study shows that most patients with GSDV will have sought
medical assessment during childhood but received an incorrect
explanation of their symptoms, providing evidence that
misdiagnosis plays an important part in delaying correct
diagnosis and implementation of appropriate medical advice.
The median diagnostic delay in patients with GSDV was 29
years, which is in accord with age of diagnosis reported
worldwide, usually between the 2nd to 5th decades [5–8].
Prevention of life-threatening complications such as acute RM,
through timely diagnosis and appropriate management of the
condition, has obvious health benefits, but also wider benefits to
the healthcare economy by reducing the need for critical care
admissions and avoiding costly treatment plans that may be
associated with diagnostic errors.
In the UK, the time from first symptoms to diagnosis has
decreased in recent decades. This could be explained by
increased awareness of the condition and the development of a
national service funded by the NHS. GSDV was first described
in 1951 [12]. Originally, diagnosis was made by forearm
exercise test showing no rise in lactate and a muscle biopsy
showing absent staining for muscle glycogen phosphorylase.
Genetic diagnosis (PYGM) became available from the late
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Fig. 1. A: Scatter plot of year of first symptoms versus delay from first symptoms to diagnosis. Diagnostic delay reduces as year of first symptoms increases; however
patients with recent onset of symptoms who are yet to be diagnosed will not have been captured. There is a dramatic increase in number of diagnoses made after
genetic testing became available in the late 1990s, with 9 diagnoses made from 1990 to 2000, and 19 from 2000 to 2010. B: Scatter plot of year of first symptoms
versus year of diagnosis.
Misdiagnosis According to Categories
Fig. 2. The total number of times misdiagnoses were reported by 45 genetically
confirmed McArdle disease patients according to the categories of misdiagnosis
and gender (female: dark grey, male: diagonal stripes). Several patients reported
more than one misdiagnosis, and so the total frequency exceeded the number
of assessed patients. RHEUM, rheumatic disorders; PSYCH, psychological
conditions; NMD, neuromuscular diseases.
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GSDV population can be diagnosed by screening the two most
common mutations (p.Arg50X and p.Gly205Ser), which is
cheap and efficient costing only £120 [8]. More recently, next
generation sequencing panels for glycogen storage diseases
and disorders associated with RM have become available,
facilitating the genetic investigation of people presenting with
exercise intolerance and/or recurrent RM [13]. In addition, the
nationally commissioned highly specialised multi-disciplinary
service for diagnosis and management of people with GSDV,
first established in 2012, has had a positive impact on
dissemination and training health care professionals. Establishing
this highly specialised service has also resulted in faster
diagnosis and improved patient care, with a documented reduction
in McArdle disease-related complications [4]. Public awareness
of the condition has also improved as a result of the work of
the Association for Glycogen Storage Disease–UK (AGSD-UK)
created in 1986 [14]. AGSD-UK has provided support to
patients in clinic, organised walking courses and produced
videos and publications [15].
Thus, improvements in the genetic diagnostic techniques,
the creation of the highly specialised service and the AGSD-UK
have positively contributed to the increase in early diagnosis.
Measures to improve the diagnosis of GSDV such as
dissemination and training were also implemented in Europe
by the Euromac registry and network funded by the Health
Programme of the European Union [10,16,17].
Even though data presented here confirmed that people are
being diagnosed with GSDV earlier in life, which seems to
correlate with a decrease in the diagnostic delay, we are unable to
confirm how many patients are still undiagnosed. Recall bias
regarding personal experiences from patients’ past medical history
is also a limitation of this study. Data acquired by the Euromac
registry will help to confirm the accuracy of the collected data and
help to determine if the decreasing trend is consistent.
5. Conclusions
In summary, misdiagnosis plays an important role in
delaying GSDV diagnosis. Addressing misdiagnosis may be an
issue of education since GSDV is a rare disorder. Efforts made
to increase the awareness of the condition in the UK as
summarised in this report suggest a positive impact in reducing
the diagnostic delay.
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